Similar articles for PMID: 26696131

Year	Number of Results
1993	1
1994	1
1999	1
2000	1
2002	2
2003	4
2004	12
2005	10
2006	2
2007	10
2008	4
2009	4
2010	6
2011	4
2012	1
2013	1
2014	2
2015	4
2016	2
2017	2
2018	1
2022	1
2023	1
2024	0

1

Long-term follow-up of previously treated and treatment-naïve patients who received tositumomab and I-131 tositumomab.

Horner TJ, Williams VC, Giampietro P, Witman PA, Lin TS. Horner TJ, et al. Leuk Lymphoma. 2016 May;57(5):1238-40. doi: 10.3109/10428194.2015.1082179. Epub 2015 Dec 23. Leuk Lymphoma. 2016. PMID: 26696131 No abstract available.

2

Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab.

Kaminski MS, Radford JA, Gregory SA, Leonard JP, Knox SJ, Kroll S, Wahl RL. Kaminski MS, et al. J Clin Oncol. 2005 Nov 1;23(31):7985-93. doi: 10.1200/JCO.2005.01.0892. Epub 2005 Oct 3. J Clin Oncol. 2005. PMID: 16204016 Clinical Trial.

3

International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related myelodysplastic syndromes and acute leukemia: overview report.

Rowley JD, Olney HJ. Rowley JD, et al. Genes Chromosomes Cancer. 2002 Apr;33(4):331-45. doi: 10.1002/gcc.10040. Genes Chromosomes Cancer. 2002. PMID: 11921269 No abstract available.

4

Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.

[No authors listed] [No authors listed] BioDrugs. 2003;17(4):290-5. doi: 10.2165/00063030-200317040-00009. BioDrugs. 2003. PMID: 12899647 Clinical Trial.

5

Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma.

Friedberg JW, Fisher RI. Friedberg JW, et al. Expert Rev Anticancer Ther. 2004 Feb;4(1):18-26. doi: 10.1586/14737140.4.1.18. Expert Rev Anticancer Ther. 2004. PMID: 14748653 Review.

6

A clinical and scientific overview of tositumomab and iodine I 131 tositumomab.

Zelenetz AD. Zelenetz AD. Semin Oncol. 2003 Apr;30(2 Suppl 4):22-30. doi: 10.1053/sonc.2003.23803. Semin Oncol. 2003. PMID: 12728404 Review.

7

Development of 131I-tositumomab.

Lewington V. Lewington V. Semin Oncol. 2005 Feb;32(1 Suppl 1):S50-6. doi: 10.1053/j.seminoncol.2005.01.014. Semin Oncol. 2005. PMID: 15786026

8

Roboz GJ, Bennett JM, Coleman M, Ritchie EK, Furman RR, Rossi A, Jhaveri K, Feldman EJ, Leonard JP. Roboz GJ, et al. Leuk Res. 2007 Aug;31(8):1141-4. doi: 10.1016/j.leukres.2006.11.011. Epub 2007 May 1. Leuk Res. 2007. PMID: 17475326

9

Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes.

Lim ZY, Pearce L, Ho AY, Barber L, Ingram W, Usai M, Tobal K, Devereux S, Pagliuca A, Mufti GJ. Lim ZY, et al. Br J Haematol. 2007 Aug;138(4):517-26. doi: 10.1111/j.1365-2141.2007.06676.x. Epub 2007 Jun 29. Br J Haematol. 2007. PMID: 17608767 Free article.

10

Tositumomab and (131)I therapy in non-Hodgkin's lymphoma.

Wahl RL. Wahl RL. J Nucl Med. 2005 Jan;46 Suppl 1:128S-40S. J Nucl Med. 2005. PMID: 15653661 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

74 results

Results by year